Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 9/20 | 0.55 |
| ▸ | CASP1 | P29466 | 9/20 | 0.55 |
| ▸ | CASP6 | P55212 | 6/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 6/20 | 0.55 |
| ▸ | CASP7 | P55210 | 5/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14598380 | 0.89 | CASP1 (0.60) | CASP3CASP1CASP6CASP8CASP7 | |
| SCHEMBL14598379 | 0.89 | CASP1 (0.60) | CASP3CASP1CASP6CASP8CASP7 | |
| SCHEMBL5496384 | 0.89 | CASP1 (0.60) | CASP3CASP1CASP6CASP8CASP7 | |
| SCHEMBL5494420 | 0.89 | CASP1 (0.60) | CASP3CASP1CASP6CASP8CASP7 | |
| SCHEMBL5490199 | 0.86 | CASP3 (0.59) | CASP3CASP1CASP6CASP8CASP7 | |
| SCHEMBL14598390 | 0.81 | ANPEP (0.52) | CASP3CASP1CASP6CASP8PSMB5 | |
| SCHEMBL5490065 | 0.81 | ANPEP (0.52) | CASP3CASP1CASP6CASP8PSMB5 | |
| SCHEMBL6830955 | 0.80 | CASP1 (0.59) | CASP3CASP1CASP7PSMB5ANPEP | |
| SCHEMBL7622869 | 0.80 | CASP3 (0.52) | CASP3CASP1CASP6CASP8CASP7 | |
| SCHEMBL7416213 | 0.80 | CASP3 (0.52) | CASP3CASP1CASP6CASP8CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157430-B2 | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | disclosed |
| US-6242422-B1 | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACUETICALS, INC. | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | CASP3 3/4885CASP1 5/4885CASP6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.